Prognostic value of TP53 transcriptional activity on p21 and bax in patients with esophageal squamous cell carcinomas treated by definitive chemoradiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 54, Issue 2, 2002, Pages 379-385

  Michel, Pierre ^a   Magois, Karine ^a   Robert, Valerie ^a   Chiron, Anne ^a   Lepessot, Florence ^a   Bodenant, Corinne ^a   Roque, Isabelle ^a   Seng, Sok H ^a   Frebourg, Thierry ^b   Paillot, Bernard ^a  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b HÔPITAL CHARLES NICOLLE   (France)

Author keywords

Chemotherapy; Esophageal carcinoma; Flow cytometry; Functional assay; Radiotherapy; Squamous cell carcinoma; TP53 immunohistochemical detection

Indexed keywords

CHEMOTHERAPY; IMMUNOLOGY; PATIENT TREATMENT; RADIOTHERAPY;

PROGNOSTIC VALUE;

ONCOLOGY;

CISPLATIN; FLUOROURACIL; PROTEIN BAX; PROTEIN P21; PROTEIN P53; SERUM ALBUMIN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MUTATION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; TREATMENT OUTCOME; WEIGHT REDUCTION; WILD TYPE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, SQUAMOUS CELL; CISPLATIN; CONFIDENCE INTERVALS; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; MUTATION; PLOIDIES; PROGNOSIS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS P21(RAS); SURVIVAL RATE; TRANS-ACTIVATION (GENETICS); TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036805253     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(02)02911-5     Document Type: Article

References (51)

1. Ménégoz F., Black R.J., Arveux P., et al. Cancer incidence and mortality in France in 1975-95. Eur J Cancer Prevent. 6:1997;442-466.
2. Katlic M.R., Wilkins E.W., Grillo H.C. Three decades of treatment of esophageal squamous carcinoma at the Massachusetts General Hospital. J Thorac Cardiovasc Surg. 99:1990;929.
3. Herskovic A., Martz K., Al-Sarraf M., et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 326:1992;1593-1598.
4. Araujo C.M., Souhami L., Gil R.A., et al. A randomized trial comparing radiation therapy versus concomitant radiation therapy and chemotherapy in carcinoma of the thoracic esophagus. Cancer. 67:1991;2258-2261.
5. Richmond J., Seydel H.G., Bae Y., et al. Comparison of three treatment strategies for esophageal cancer within a single institution. Int J Radiat Oncol Biol Phys. 13:1987;1617-1620.
6. Coia L., Engstrom P.A., Paul A.R., et al. Long term results of infusional 5-FU, mitomycin C and radiation as primary management of esophageal carcinoma. Int J Radiat Oncol Biol Phys. 20:1991;29-36.
7. Seitz J.F., Giovannini M., Padaut-Cesana J., et al. Inoperable nonmetastatic squamous cell carcinoma of the esophagus managed by concomitant chemotherapy (5-fluorouracil and cisplatin) and radiation therapy. Cancer. 66:1990;214-219.
8. Raoul J.L., Le Prisé E., Meunier B., et al. Combined radiochemotherapy for postoperative recurrence of oesophageal cancer. Gut. 37:1995;174-176.
9. Forastiere A.A., Orringer M.B., Perez-Tamayo C., et al. Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus Final report . J Clin Oncol. 11:1993;1118-1123.
10. Mandard A.M., Dalibard F., Mandard J.C., et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Cancer. 73:1994;2680-2686.
11. Stahl M., Wilke H., Fink U., et al. Combined preoperative chemotherapy and radiotherapy in patients with locally advanced esophageal cancer Interim analysis of a phase II trial . J Clin Oncol. 14:1996;829-837.
12. Adelstein D.J., Rice T.W., Becker M., et al. Use of concurrent chemotherapy, accelerated fractionation radiation, and surgery for patients with esophageal carcinoma. Cancer. 80:1997;1011-1120.
13. Bosset J.F., Gignoux M., Triboulet J.P., et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous cell cancer of the esophagus. N Engl J Med. 337:1997;161-167.
14. Seitz J.F., Milan C., Giovannini M., et al. Concurrent concentrated chemoradiation therapy in squamous cell carcinoma of the esophagus Long term results of a national multicenter phase II study in 122 inoperable patients (FFCD 8803) . Gastroenterol Clin Biol. 24:2000;201-210.
15. Beatty J.D., De Baer G., Rider W.D. Carcinoma of the oesophagus; pretreatment assessment correlation of radiation treatment parameters with survival and identification and management of radiation treatment failure. Cancer. 43:1979;2254-2267.
16. Bedenne L., Seitz J.F., Milan C., et al. Preoperative cisplatin, 5 FU, and radiotherapy in squamous cell esophageal carcinoma Multicentric phase II trial FFCD 8804 . Gastroenterol Clin Biol. 22:1998;273-281.
17. Roth J.A., Pars H.I., Flanagan M.M., et al. Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus. J Cardiovasc Surg. 96:1988;242-248.
18. Charlois T., Burtin P., Ben Bouali A.K., et al. Predictive factors of response to chemotherapy for esophageal squamous cell carcinoma Study of 60 patients and proposal of a response score . Gastroenterol Clin Biol. 16:1992;134-140.
19. Cooke L.D., Cooke T.G., Bootz F., et al. Ploidy as a prognostic indicator in end stage squamous cell carcinoma of the head and neck region treated with cisplatinum. Br J Cancer. 61:1990;759-762.
20. Franzen G., Klinterberg C., Olofsson J., et al. DNA measurement An objective predictor of response to irradiation? A review of 24 squamous cell carcinoma of the oral cavity . Br J Cancer. 53:1986;643-651.
21. Seitz J.F., Perrier H., Monges G., et al. Multivariate analysis of the prognostic factors of survival and the response to treatment of squamous cell oesophageal cancer by concomitant radiochemotherapy Value of p53 immunodetection . Gastroenterol Clin Biol. 19:1995;465-474.
22. Ségalin A., Ruol A., Panozzo M., et al. Flow cytometric analysis does not predict the radiochemoresponsiveness of oesophageal cancer. J Surg Oncol. 54:1993;87-90.
23. Jung M., Notario V., Dritschilo A. Mutations in the p53 gene in radiosensitive and resistant human squamous carcinoma cells. Cancer Res. 52:1992;6390-6393.
24. Raybaud-Diogene H., Fortin A., Morency R., et al. Markers of radio resistance in squamous cell carcinoma of the head and neck A clinicopathologic and immunohistochemical study . J Clin Oncol. 15:1997;1030-1038.
25. Muro K., Ohtsu A., Boku N., et al. Association of p53 protein expression with responses and survival of patients with locally advanced oesophageal carcinoma treated with chemoradiotherapy. Jpn J Clin Oncol. 26:1996;65-69.
26. Puglisi F., Di Loreto C., Panizzo R., Avellini C., Fongione S., Cacitti V., et al. Expression of p53 and bcl 2 and response to preoperative chemotherapy and radiotherapy for locally advanced squamous cell carcinoma of the oesophagus. J Clin Pathol. 49:1996;456-459.
27. Lam K.Y., Law S., Ma L.T., et al. Preoperative chemotherapy for squamous cell carcinoma of the oesophagus Do histological assessment and p53 over-expression predict chemo-responsiveness? Eur J Cancer. 33:1997;1221-1225.
28. Ribeiro U., Finkelstein S.D., Safatie-Ribeiro A.V., et al. p53 sequence analysis predicts treatment response outcome of patients with oesophageal carcinoma. Cancer. 83:1998;7-18.
29. Goggi G., Bosari S., Roncalli M., et al. p53 protein accumulation and p53 gene mutation in esophageal carcinoma. Cancer. 79:1997;425-432.
30. Lowe S., Bodis S., McClatchey A., et al. p53 status and the efficacy of cancer therapy in vivo. Science. 266:1994;807-810.
31. Ludwig R.L., Bates S., Vousden K.H. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol Cell Biol. 16:1996;4952-4960.
32. Audrezet M.P., Robaszkiewicz M., Mercier B., et al. TP 53 gene mutation profile in oesophageal squamous cell carcinoma. Cancer Res. 53:1993;5741-5749.
33. Imazeki F., Omata M., Nose H., et al. p53 gene mutation in gastric and esophageal cancers. Gastroenterology. 103:1992;892-896.
34. Muzeau F., Flejou J.F., Potel F., et al. Profile of p53 gene mutation and abnormal expression of p53 protein in the two types of esophageal cancer. Gastroenterol Clin Biol. 20:1996;430-437.
35. Flaman J.M., Robert V., Lenglet S., et al. Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast. Oncogene. 16:1998;1369-1372.
36. Flaman J.M., Frebourg T., Moreau V., et al. A simple p53 functional assay for screening cell lines, blood and tumors. Proc Natl Acad Sci USA. 92:1995;3963-3967.
37. Coia L.R., Minsky B.D., Berkey B.A., et al. Outcome of patients receiving radiation for cancer of the esophagus Results of the 1992-1994 patterns of care study . J Clin Oncol. 18:2000;455-462.
38. Kelsen D.P., Heelan R., Coonley C., et al. Clinical and pathological evaluation of response to chemotherapy in patients with oesophageal carcinoma. Am J Clin Oncol. 6:1983;539-546.
39. Jones D.R., Parker L.A., Detterbeck F.C., et al. Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy. Cancer. 85:1999;1026-1032.
40. Wood G.S., Warnke R. Suppression of endogenous avidin-binding activity in tissues and its relevance to biotin-avidin detection systems. J Histochem Cytochem. 29:1981;1196-1204.
41. Guillaud M., Matthews J.B., Harrisson A., et al. A novel image cytometric method for quantitation of immunohistochemical staining of cytoplasmic antigen. Anal Cell Pathol. 14:1997;87-99.
42. Frebourg T., Flaman J.M., Estreicher A., et al. Functional assay of the p53 tumor suppressor gene. Cotton R.G.H., Edkins E., Forrest S.M., Mutation detection a practical approach . 1998;211-222 Oxford University Press, Oxford, U.K.
43. Shankey T.V., Rabinovitch P.S., Bagwell B., et al. Guidelines for implementation of clinical DNA cytometry. Cytometry. 14:1993;472-477.
44. Robert V., Michel P., Flaman J.M., et al. High frequency in oesophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis. Carcinogenesis. 21:2000;563-565.
45. Wang D.Y., Xiang Y.Y., Tanaka M., et al. High prevalence of p53 protein overexpression in patients with esophageal cancer in Linxian, China and its relation to progression and prognosis. Cancer. 74:1994;3089-3096.
46. Sarbia M., Porschen R., Borchard F., et al. p53 protein expression and prognosis in squamous cell carcinoma of the esophagus. Cancer. 74:1994;2218-2223.
47. Poplin E.A., Jacobson J., Herskovic A., et al. Evaluation of multimodality treatment of locoregional esophageal carcinoma by Southwest Oncology Group 9060. Cancer. 78:1996;1851-1856.
48. Ito T., Kaneko K., Makino R., et al. Prognostic value of p53 mutations in patients with locally advanced esophageal carcinoma treated with definitive chemoradiotherapy. J Gastroenterol. 36:2001;303-311.
49. Soontrapornchai P., Elsaleh H., Joseph D., et al. TP53 gene mutation status in pre-treatment biopsies of oesophageal adenocarcinoma has no prognostic value. Eur J Cancer. 35:1999;1683-1687.
50. Ireland A.P., Shibata D.K., Chandrasoma P., et al. Clinical significance of p53 mutations in adenocarcinoma of the esophagus and cardia. Ann Surg. 231:2000;179-187.
51. Trott K.R. Cell repopulation and overall treatment time. Int J Radiat Oncol Biol Phys. 19:1990;1071-1075.